Evidence map›Paper›PMID 30858524›Full record

ArticleScientific reports2019

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells.

Amalia Azzariti, Rosa Maria Iacobazzi, Roberta Di Fonte, Letizia Porcelli, Roberto Gristina, Pietro Favia, Francesco Fracassi, Ilaria Trizio, Nicola Silvestris, Gabriella Guida and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Amalia AzzaritiExperimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy. a.azzariti@oncologico.bari.it.
Rosa Maria IacobazziExperimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.
Roberta Di FonteExperimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.
Letizia PorcelliExperimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.
Roberto GristinaInstitute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.
Pietro FaviaInstitute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.
Francesco FracassiInstitute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.
Ilaria TrizioDepartment of Chemistry, University of Bari Aldo Moro Via Orabona 4, Bari, 70126, Italy.
Nicola SilvestrisScientific Direction, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.ORCID 0000-0001-7814-7318
Gabriella GuidaDepartment of Basic Medical Sciences, Neurosciences and Sense Organs -University of Bari Aldo Moro via Orabona 4, Bari, 70126, Italy.
Stefania TommasiMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.
Eloisa SardellaInstitute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy. eloisa.sardella@cnr.it.
Istituto Tumori Bari · ITIstituto di Nanotecnologia · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, cold atmospheric plasmas have shown promising application in cancer therapy. The therapeutic use of plasma-activated media is a topic addressed in an emerging field known as plasma pharmacy. In oncology, plasma-activated media are  used to harness the therapeutic effects of oxidant species when they come in contact with cancer cells. Among several factors that contribute to the anticancer effect of plasma-activated liquid media (PALM), H

Indexed as

CalreticulinCell DeathCell Line, TumorCell SurvivalCulture MediaElectricityHumansHydrogen PeroxideMelanomaNitritesPancreatic NeoplasmsPlasma GasesSignal Processing, Computer-AssistedCalreticulinCALR protein, humanCulture MediaHydrogen PeroxideNitritesPlasma Gases

Identifiers

PMID30858524
PMCPMC6411873
OpenAlexW2922266838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.